The New Drugs and Unforeseen Consequences
A discouraging number of lawsuits involving the new weight-loss drugs are currently underway, with potentially thousands more waiting in the wings.
Views on New Drugs Vary
The new weight-loss meds do not treat the root causes of obesity, just like asthma drugs don’t treat air quality and pain relievers don’t prevent injury.
New Drugs — Does Lifestyle Intervention Still Count? Part 5
To put it bluntly, weight loss drugs don’t work unless the patient is also involved in some aspect of what the drug makers define as intervention.
New Drugs — Does Lifestyle Intervention Still Count? Part 4
Do the new, remarkably effective GLP-1 obesity medications eliminate the need for obesity interventions such as the BrainWeighve app?
New Drugs — Does Lifestyle Intervention Still Count? Part 3
Tirzepatide, a medication combining semaglutide with another GLP-1 agonist, known as Mounjaro, is approved for type 2 diabetes but widely used for weight loss.
New Drugs — Does Lifestyle Intervention Still Count? Part 2
Do the new, remarkably effective GLP-1 obesity medications eliminate the need for obesity interventions?
New Drugs — Does Lifestyle Intervention Still Count? Part 1
Today’s question is: Do the new, remarkably effective GLP-1 obesity medications eliminate the need for obesity interventions such as BrainWeighve?
Personality, Behavior, and the New Weight Loss Drugs, Part 2
Like many other things in life, obesity is multifactorial. One factor is, some folks are not reachable by logic, or even by an appeal to their self-interest.
Personality, Behavior, and the New Weight Loss Drugs
Here are some interesting results of a brand new multi-author meta-analysis of information on personality traits associated with childhood obesity.
The -tide Drugs: Enthusiasm Runs Hot and Cold
For the past few months, the -tide drugs (GLP-1 agonists) have dominated obesity news. The debate over the new weight-loss drugs is ongoing.